Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6163
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAnna Kalffen
dc.contributor.authorJake Shortten
dc.contributor.authorFlora Yuenen
dc.contributor.authorJohn Reynoldsen
dc.contributor.authorHang Quachen
dc.contributor.authorCraig Wallington-Gatesen
dc.contributor.authorPatricia Walkeren
dc.contributor.authorSimon Harrisonen
dc.contributor.authorDunn Rosanneen
dc.contributor.authorAndrew Spenceren
dc.date.accessioned2024-08-08T02:55:14Z-
dc.date.available2024-08-08T02:55:14Z-
dc.date.issued2019-
dc.identifier.citationHemaSphere, 2019en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6163-
dc.description.abstractBackground:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.en
dc.language.isoenen
dc.publisherWolters Kluwer Healthen
dc.titleA Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)en
dc.typeArticleen
dc.identifier.doi10.1097/01.HS9.0000563808.41508.98-
dc.rights.holderCraig Wallington-Gatesen
dc.identifier.journaltitleHemaSphere-
dc.identifier.external108884836-
item.languageiso639-1en-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Sites:Sunshine Coast HHS Publications
Show simple item record

Page view(s)

74
checked on Jan 4, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.